Cargando…

The Early Experience With Vedolizumab in the United States

BACKGROUND: Post-marketing studies of new inflammatory bowel disease (IBD) therapies are needed to establish clinical effectiveness and safety in clinical practice. We aimed to describe the U.S. experience with vedolizumab in a commercially insured population. METHODS: We conducted a retrospective c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kochar, Bharati, Jiang, Yue, Winn, Aaron, Barnes, Edward L, Martin, Christopher F, Long, Millie D, Kappelman, Michael D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Observations And Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798787/ https://www.ncbi.nlm.nih.gov/pubmed/31667469 http://dx.doi.org/10.1093/crocol/otz027

Ejemplares similares

Home Infusions for Inflammatory Bowel Disease Are Safe: US Experience and Patient Perspectives
por: Kochar, Bharati, et al.
Publicado: (2021)

Comparing Patient-Reported Outcomes Among Anti-TNF Experienced Patients With Ulcerative Colitis Initiating Vedolizumab Versus Tofacitinib
por: Kappelman, Michael D, et al.
Publicado: (2023)

Trends and Characteristics of Clinical Trials Participation for Inflammatory Bowel Disease in the United States: A Report From IBD Partners
por: Johnson, Cole, et al.
Publicado: (2020)

Chronic Antibiotic Dependent Pouchitis Is Associated With Older Age at the Time of Ileal Pouch Anal Anastomosis (J-pouch) Surgery
por: Weaver, Kimberly N, et al.
Publicado: (2019)

A Patient-Prioritized Agenda for Information Needs During the COVID-19 Pandemic: A Qualitative Study of Patients With Inflammatory Bowel Disease
por: Long, Millie D, et al.
Publicado: (2021)

Vedolizumab Experience in Children and Adolescents With Inflammatory Bowel Disease: A Multicenter Observational Study
por: Hajjat, Temara M, et al.
Publicado: (2021)

Disease and Treatment Patterns Among Patients With Pouch-related Conditions in a Cohort of Large Tertiary Care Inflammatory Bowel Disease Centers in the United States
por: Barnes, Edward L, et al.
Publicado: (2020)

Prevalence of Immunomodulator Use as Combination Therapy With Vedolizumab or Ustekinumab in Inflammatory Bowel Disease
por: Lutz, Megan, et al.
Publicado: (2023)

Risks of Development of COVID-19 Among Patients With Inflammatory Bowel Disease: A Comparative Assessment of Risk Factors for Incident Infection
por: Long, Millie D, et al.
Publicado: (2022)

Favorable Outcomes Combining Vedolizumab With Other Biologics or Tofacitinib for Treatment of Inflammatory Bowel Disease
por: Llano, Ernesto M, et al.
Publicado: (2021)

Real-World Effectiveness of Vedolizumab Dose Escalation in Patients With Inflammatory Bowel Disease: A Systematic Literature Review
por: Patel, Dipen, et al.
Publicado: (2022)

Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn’s Disease: Post Hoc Analyses of VISIBLE Studies
por: Sandborn, William J, et al.
Publicado: (2023)

Evaluation of the Optimal Position for Vedolizumab in the Japanese Treatment Paradigm for Ulcerative Colitis Using Markov Modeling
por: Uda, Akihito, et al.
Publicado: (2020)

CT or MR Enterography to Assess Response During Vedolizumab Therapy for Small Bowel Crohn’s Disease
por: Kwapisz, Lukasz, et al.
Publicado: (2022)

The Immunogenicity of the Influenza, Pneumococcal, and Hepatitis B Vaccines in Patients With Inflammatory Bowel Disease Treated With Vedolizumab
por: Harrington, Jill E, et al.
Publicado: (2020)

Vedolizumab in Mild-to-Moderate Crohn’s Disease Patients Naïve to Biological Therapy: A Multicentric Observational Study
por: Dotti, Adriana Zanoni, et al.
Publicado: (2023)

Functional Molecular Network Analysis Enables Prediction of Response to Vedolizumab Therapy in Anti-TNF Refractory IBD Patients
por: Breidert, Matthias, et al.
Publicado: (2020)

Patient-Preferences Favoring Treatment Discontinuation Are Reduced With Vedolizumab and Ustekinumab Compared With TNF Antagonists in Inflammatory Bowel Disease
por: Kumar, Anand, et al.
Publicado: (2020)

Economic Outcomes of Inflammatory Bowel Disease Patients Switching to a Second Anti-Tumor Necrosis Factor or Vedolizumab
por: Chiorean, Michael, et al.
Publicado: (2020)

Origin, Evolution, and Genotyping of Emergent Porcine Epidemic Diarrhea Virus Strains in the United States
por: Huang, Yao-Wei, et al.
Publicado: (2013)

Adalimumab, Infliximab, and Vedolizumab in Treatment of Ulcerative Colitis: A Long-Term Retrospective Study in a Tertiary Referral Center
por: Gagnon, Ann-Lorie, et al.
Publicado: (2021)

Colistin Heteroresistance Is Largely Undetected among Carbapenem-Resistant Enterobacterales in the United States
por: Band, Victor I., et al.
Publicado: (2021)

Genomic Analysis of a Pan-Resistant Isolate of Klebsiella pneumoniae, United States 2016
por: de Man, Tom J. B., et al.
Publicado: (2018)

Treatment Patterns and Standardized Outcome Assessments Among Patients With Inflammatory Conditions of the Pouch in a Prospective Multicenter Registry
por: Barnes, Edward L, et al.
Publicado: (2022)

Adalimumab Is Associated With Lower Healthcare Resource and Steroid Use Versus Vedolizumab in Biologic-Naive Crohn’s Disease: A Retrospective Claims Database Analysis
por: Ungaro, Ryan C, et al.
Publicado: (2022)

Probability of Response as Defined by a Clinical Decision Support Tool Is Associated With Lower Healthcare Resource Utilization in Vedolizumab-Treated Patients With Crohn’s Disease
por: Dulai, Parambir S, et al.
Publicado: (2022)

Trends in Surgical Recurrence Among Pediatric Crohn’s Disease Patients Using Administrative Claims Data
por: Egberg, Matthew D, et al.
Publicado: (2023)

Colistin- and Carbapenem-Resistant Escherichia coli Harboring mcr-1 and bla(NDM-5), Causing a Complicated Urinary Tract Infection in a Patient from the United States
por: Mediavilla, José R., et al.
Publicado: (2016)

An Asian Origin of Virulent Aeromonas hydrophila Responsible for Disease Epidemics in United States-Farmed Catfish
por: Hossain, Mohammad J., et al.
Publicado: (2014)

Characteristics of Fecal Microbiota Transplantation Use in Inflammatory Bowel Disease Cohort
por: Bauer, Christina M, et al.
Publicado: (2020)

The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry
por: Agrawal, Manasi, et al.
Publicado: (2021)

Dietary Patterns Are Not Associated With Disease Activity Among Patients With Inflammatory Conditions of the Pouch in a Prospective Cohort
por: Barnes, Edward L, et al.
Publicado: (2023)

Methodology and Initial Results From a Real-World Observational Cohort of Patients With Inflammatory Bowel Disease: TARGET-IBD
por: Click, Benjamin, et al.
Publicado: (2021)

Measuring Serum Vedolizumab and Vedolizumab Antibodies: Comparison of Commercial Assays with the Vedolizumab Clinical Development Assay
por: Vande Casteele, Niels, et al.
Publicado: (2023)

Hospital resource intensity and cirrhosis mortality in United States
por: Mathur, Amit K, et al.
Publicado: (2017)

Persistence, Dosing, and Other Treatment Patterns Among Crohn’s Disease Patients Initiating Biologics in United States
por: Teeple, Amanda, et al.
Publicado: (2021)

The Epidemiology of Respiratory Failure in the United States 2002–2017: A Serial Cross-Sectional Study
por: Kempker, Jordan A., et al.
Publicado: (2020)

The Epidemiology of Adult Tracheostomy in the United States 2002–2017: A Serial Cross-Sectional Study
por: Abril, Maria K., et al.
Publicado: (2021)

Fr494 THE IMPACT OF VEDOLIZUMAB THERAPY ON COVID-19 OUTCOMES IN ADULT IBD PATIENTS IN THE SECURE-IBD REGISTRY
por: Agrawal, Manasi, et al.
Publicado: (2021)

Direct costs of carcinoid syndrome diarrhea among adults in the United States
por: Dasari, Arvind, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7t38mshtbes5dd3qqpr8kir6md